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Abstract 
Intravenous fluid administration should be considered as any other pharmacological prescription. There are three 
main indications: resuscitation, replacement, and maintenance. Moreover, the impact of fluid administration as drug 
diluent or to preserve catheter patency, i.e., fluid creep, should also be considered. As for antibiotics, intravenous fluid 
administration should follow the four Ds: drug, dosing, duration, de-escalation. Among crystalloids, balanced solu-
tions limit acid–base alterations and chloride load and should be preferred, as this likely prevents renal dysfunction. 
Among colloids, albumin, the only available natural colloid, may have beneficial effects. The last decade has seen 
growing interest in the potential harms related to fluid overloading. In the perioperative setting, appropriate fluid 
management that maintains adequate organ perfusion while limiting fluid administration should represent the stand-
ard of care. Protocols including a restrictive continuous fluid administration alongside bolus administration to achieve 
hemodynamic targets have been proposed. A similar approach should be considered also for critically ill patients, in 
whom increased endothelial permeability makes this strategy more relevant. Active de-escalation protocols may be 
necessary in a later phase. The R.O.S.E. conceptual model (Resuscitation, Optimization, Stabilization, Evacuation) sum-
marizes accurately a dynamic approach to fluid therapy, maximizing benefits and minimizing harms. Even in specific 
categories of critically ill patients, i.e., with trauma or burns, fluid therapy should be carefully applied, considering the 
importance of their specific aims; maintaining peripheral oxygen delivery, while avoiding the consequences of fluid 
overload.
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Introduction
Intravenous fluids have been in clinical use for over a 
century, yet the medical and scientific community have 
only recently begun to appreciate the importance of judi-
cious fluid administration, the necessity to handle them 
as any other drug we prescribe [1–4], and the consider-
able side effects with which they may be associated [5, 6].
Three major indications exist for intravenous fluid 
administration [1, 4, 7–9]: resuscitation, replacement, 
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and maintenance. Resuscitation fluids are used to correct 
an intravascular volume deficit or acute hypovolemia; 
replacement solutions are prescribed to correct exist-
ing or developing deficits that cannot be compensated 
by oral intake alone [6]; maintenance solutions are indi-
cated in hemodynamically stable patients that are not 
able/allowed to drink water in order to cover their daily 
requirements of water and electrolytes [10, 11]. In addi-
tion to these classical indications, the quantitative rel-
evance of fluids administered as drug diluents and to 
guarantee catheter patency, the so-called fluid creep, has 
been recently underlined [12, 13].
Although the use of intravenous fluids is one of the 
most common interventions in medicine, the ideal fluid 
does not exist. In light of recent evidence, a reappraisal 
of how intravenous fluids should be used in the perio-
perative and critical care setting is warranted. Here, we 
present the executive summary on this area of the Inter-
national Fluid Academy (https ://www.fluid acade my.org).
The four Ds of fluid management
Similarly to antibiotics, the 4 Ds of fluid therapy need to 
be considered (Table 1) [4].
Drug
Fluids are drugs with indications, contraindications, and 
side effects. Different indications need different types of 
fluids, e.g., resuscitation fluids should focus on rapid res-
toration of circulating volume; replacement fluids must 
mimic the fluid that has been lost; maintenance fluids 
must deliver basic electrolytes and glucose for metabolic 
needs.
Dosing
The dose makes the poison, as stated by Paracelsus. How-
ever, timing and administration rate are equally impor-
tant for fluids [14, 15]. Of note, in contrast to most drugs, 
there is no standard therapeutic dose for fluids.
Duration
The duration of fluid therapy is crucial and volume 
must be tapered when shock is resolved. However, while 
“starting triggers” for fluid resuscitation are quite clear, 
clinicians are less aware of “stopping triggers” of fluid 
resuscitation.
De‑escalation
The final step in fluid therapy is to withhold/withdraw 
fluids when they are no longer required, thus reducing 
the risk of fluid overload and related deleterious effects 
[16].
Balanced solutions
The basics
Intravenous “balanced” solutions include crystalloids 
and colloids with minimal effect on the homeostasis 
of the extracellular compartment, and in particular on 
acid–base equilibrium and electrolyte concentrations 
[3]. In addition, the term “balanced” has been recently 
applied also to fluids with a low chloride content  (Cl−). 
Therefore, there are two main categories of balanced 
solutions (Table 2): (1) fluids causing a minimal effect on 
acid–base equilibrium, having an electrolyte content with 
an in vivo strong ion difference (SID), i.e., the SID after 
metabolism of the organic anion, close to 24–29 mEq/L; 
(2) fluids having a normal or sub-normal  Cl− content 
 (Cl− ≤ 110 mEq/L).
According to the quantitative approach to acid–base 
equilibrium [17, 18], the three variables regulating the 
pH of biologic fluids independently are (1) partial pres-
sure of carbon dioxide  (PCO2); (2) the concentration of 
non-volatile weak acids (ATOT); (3) the strong ion differ-
ence (SID), defined as the difference between the sum of 
all strong cations and the sum of all strong anions [19]. 
These principles clearly suggest that intravenous fluids 
may affect pH due to (i) the specific electrolyte content 
characterizing the solution, therefore altering the SID of 
the extracellular compartment and (ii) the dilution effect 
due to the volume infused, thus reducing the concen-
tration of ATOT [20–22]. Ideally, the fluid able to leave 
plasma pH unchanged after its administration, at con-
stant  PCO2, should balance these variations. Recent stud-
ies clearly showed that, in this regard, the ideal balanced 
solution should have an in vivo SID equal to the baseline 
concentration of  HCO3− [23]. If the SID of the infused 
fluid is greater than plasma  HCO3−, plasma pH will tend 
toward alkalosis; if the SID of the infused fluid is lower 
than plasma  HCO3−, plasma pH will tend toward acido-
sis, as it is always the case for NaCl 0.9%, the so-called 
“normal” saline [24].
As stated above, the definition of “balanced” solu-
tion includes also a category of iso- and near-isotonic 
fluids with a low  Cl− content (equal to or lower than 
110  mEq/L), as compared to NaCl 0.9%. Nonetheless, 
the final composition of such a fluid, especially when 
considering crystalloids, will depend on (1) tonicity; (2) 
electrical neutrality and (3) SID. Indeed, an isotonic bal-
anced solution leaving unaltered acid–base equilibrium 
(i.e., with an SID close to 24 mEq/L) will necessarily have 
a  Cl− content > 110  mEq/L (as in Sterofundin-ISO). In 
contrast, a fluid with an SID of 24  mEq/L and a lower 
 Cl− content will necessarily be slightly hypotonic (as with 
Lactated Ringer’s). Finally, an isotonic fluid with a low 
 Cl− content will necessarily have a higher SID (as with 
PlasmaLyte), with a consequent alkalizing effect.
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The case for balanced solutions
Balanced and unbalanced (NaCl 0.9%) solutions might 
have slightly different effects on blood volume expan-
sion, according to the clinical condition. Indeed, different 
kinetics showing approximately a 10% decrease in plasma 
volume expansion of balanced solutions as compared to 
NaCl 0.9% have been described in normovolemic healthy 
volunteers [25, 26]. On the other hand, in an experimen-
tal model of near-fatal hemorrhagic shock, a lower dose 
of balanced solution was needed, as compared to NaCl 
0.9% to restore a target blood pressure [27]. These con-
flicting results underline the fact that findings about fluid 
therapy are condition-specific, and that results obtained 
from septic patients or experimental models should not 
be extrapolated to all situations.
Despite these controversies, which need further clarifi-
cation, several definitive differences exist between these 
two categories of drugs. First, chloride-rich NaCl 0.9% 
causes a higher dose-dependent degree of acidosis and 
hyperchloremia, which possibly favors the contraction of 
vascular smooth muscles [28, 29], potentially leading to a 
reduced renal perfusion.
When healthy volunteers received 2 L of either saline 
or Plasma-Lyte over 1  h, saline significantly decreased 
renal artery blood velocity, decreased renal cortical 
tissue perfusion, decreased urine output, and increased 
extravascular fluid accumulation compared with Plasma-
Lyte [30]. These findings may support the idea that 
hyperchloremia may cause increased tubule-glomerular 
feedback and decreased renal cortical perfusion [31].
Indeed, a large-scale propensity-matched observa-
tional analysis of U.S. insurance data showed that the 
use of  PlasmaLyte® versus NaCl 0.9% on the first day of 
major abdominal surgery led to significantly less renal 
failure requiring dialysis [32]. In addition to the effect 
on renal perfusion, NaCl 0.9%, being slightly hypertonic, 
likely causes an increased incretion of arginine vaso-
pressin. These two effects can conceivably contribute to 
the slower renal excretion of NaCl 0.9% as compared to 
balanced solutions [33, 34]. Indeed, more fluid will be 
retained in the interstitial space, with the consequent 
propensity to cause more edema [35, 36]. However, it 
is not merely the renal function that could be deranged 
by high chloride concentrations; infusion of NaCl 0.9% 
can cause abdominal discomfort in healthy volunteers 
[37] and a reduced gastric perfusion in elderly surgical 
patients [38].
Two important and large randomized controlled tri-
als comparing the use of balanced solutions and normal 
saline have been published in the last years. The SPLIT 
Table 2 Electrolyte composition of the main balanced solutions available for intravenous administration. Adapted from 
Langer et al. [21] with permission
In-vivo SID—all organic molecules contained in balanced solutions are strong anions. The resulting calculated SID (in vitro-SID) is equal to 0 mEq/L, due to electrical 
neutrality. Once infused, the organic molecules are metabolized to  CO2 and water; the resulting in vivo-SID corresponds to the amount of organic anions metabolized
a Sterofundin-ISO or Ringerfundin
b In vivo-SID of Tetraspan reported in the Table results from the sum of organic anions; of note, there is a discrepancy as compared to the SID calculated as the 
difference between inorganic cations and inorganic anions (29 mEq/L vs. 33 mEq/L). No clear explanation has been reported from the seller
Crystalloids Gelatins Starches
Lactated 
Ringer’s
Acetated 
Ringer’s
Hartmann’s PlasmaLyte Sterofundin 
 ISOa
ELO‑
MEL 
isoton
Isoplex Gelaspan Hextend Tetraspan
Na+ [mEq/L] 130 132 131 140 145 140 145 151 143 140
K+ [mEq/L] 4 4 5 5 4 5 4 4 3 4
Ca2+ [mEq/L] 3 3 4 – 5 5 – 2 5 5
Mg2+ [mEq/L] – – 3 3 2 3 1.8 2 0.9 2
Cl− [mEq/L] 109 110 111 98 127 108 105 103 124 118
Lactate [mEq/L] 28 – 29 – – – 25 – 28 –
Acetate [mEq/L] – 29 – 27 24 45 – 24 – 24
Malate [mEq/L] – – – – 5 – – – – 5
Gluconate [mEq/L] – – – 23 – – – – – –
Dextrose [g L-1] – – – – – – – – – –
Gelatin [g/L] – – – – – – 40 40 – –
HES [g/L] – – – – – – – – 60 60
Dextran [g/L] – – – – – – – – – –
In-vivo SID [mEq/L] 28 29 29 50 29 45 45.8 56 28 29b
Osmolarity [mOsm/L] 278 277 279 294 309 302 284 284 307 297
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study was the first multi-center double-blind rand-
omized controlled trial performed on 2092 patients, 
comparing balanced and unbalanced fluids in intensive 
care units. It showed no significant difference in the 
main outcome, i.e., incidence of acute kidney injury 
[39]. While providing a high level of evidence, this trial 
did not give a definitive answer. Indeed, the median 
volume of study fluid was only 2 L over 90 days. More-
over, both study groups had received a median volume 
of 1.0–1.2 L of PlasmaLyte within 24 h prior to enrol-
ment, therefore making it plausible that prior admin-
istration of PlasmaLyte counterbalanced the effects 
of low-dose NaCl 0.9%. The SMART-trial was a large 
study performed in five intensive care units of a sin-
gle academic center [40]. A total of 15,802 patients 
were randomized to receive either NaCl 0.9% or a bal-
anced solution (Plasma-Lyte A or Lactated Ringer’s). 
In both groups, patients received an extremely small 
amount of fluids: a median of 1  L from admission to 
day 30 or discharge, whichever came first. Despite the 
unexpectedly low volume of crystalloids, the authors 
found a small difference in the primary outcome, i.e., 
the incidence of major adverse kidney events within 
30  days (composite of death, new renal replacement 
therapy or persistent renal dysfunction) in favor of bal-
ance solutions. Looking at the overall outcome, it is 
important to emphasize that there was no reduction of 
in-hospital mortality and that neither the incidence of 
renal replacement therapy (2.5% vs. 2.9%, p = 0.08) nor 
the incidence of persistent renal dysfunction (6.4% vs. 
6.6%, p = 0.60) was statistically significant. A similar 
study performed by the same authors and published 
in the same issue of the New England Journal of Medi-
cine, the SALT-ED trial, found a similar difference in 
the incidence of major adverse kidney events in non-
critically ill adults [41].
In summary, we can avoid fluid-induced metabolic 
acidosis and excessive chloride loading simply using 
balanced solutions. There is increasing evidence that 
an excessive chloride administration may have a det-
rimental effect on renal function, even at low doses. 
Therefore, the use of balanced solutions, particularly 
in patients that potentially need a significant amount 
of intravenous fluids, seems to be a reasonable prag-
matic choice [42]. On the contrary, saline may be an 
intuitive choice for patients with hypovolemic hypona-
tremia or hypochloremic metabolic alkalosis. In any 
other settings, the most important reason to choose 
NaCl 0.9% over balanced solutions is likely economic 
in nature. Therefore, the patient’s serum chloremia is 
an important factor to determine the appropriate type 
of fluids.
Albumin
The basics
Albumin accounts for approximately 50% of the plasma 
protein content [43] and is the main determinant of 
plasma oncotic pressure, playing a crucial role in the 
regulation of microvascular fluid dynamics [44, 45]. Nor-
mal plasma concentration of albumin ranges between 
35 and 55  g/L, corresponding to approximately 0.54–
0.85  mmol/L, and to an in  vitro pressure of approxi-
mately 9.2  mmHg. In contrast, in  vivo colloid-oncotic 
pressure is lower, since the permeability of the endothe-
lial barrier to albumin is variable, even in healthy sub-
jects. Nonetheless, according to Starling’s law, oncotic 
pressure is the force counteracting intravascular hydro-
static pressure, therefore acting to reabsorb water and 
small solutes from the interstitium to the intravascular 
space. The crucial role of albumin’s oncotic property in 
the regulation of microcirculatory fluid dynamics also 
seems to apply to the endothelial glycocalyx layer [46, 
47]. This gel-like layer, lining the luminal side of the 
endothelium, is thought to comprise 20% of the intra-
vascular volume. The current view of the glycocalyx is 
that it holds many compounds that are mandatory for 
the functioning of the endothelium and mediates several 
key physiological processes, such as maintaining the vas-
cular barrier, hemostasis, prevention of cell adhesion to 
the endothelium and transmission of shear stress [48]. 
The role of the glycocalyx is however under continuous 
investigation and its role and function might need to be 
revised in the future [49]. Of note, shedding of the glyco-
calyx occurs in the presence of reactive oxygen species, 
hyperglycemia, cytokines, and endotoxin, and is there-
fore common in critically ill patients [50]. In the context 
of fluid homeostasis, loss of barrier function induced by 
glycocalyx shedding is associated with the formation of 
edema [51]. Furthermore, fluid therapy itself is known to 
be potentially deleterious for endothelial function [27], 
likely because of the resulting oxidative stress. However, 
the risks probably relate to the specific clinical context. 
Indeed, while volume loading did not cause glycocalyx 
shedding in surgical patients and healthy volunteers [52, 
53], the amount of glycocalyx shedding was proportional 
to the volume of fluid given in septic shock patients [54].
The case for albumin
The ALBIOS study, a large Italian randomized controlled 
trial, gave some suggestions on whether or not albumin 
administration improves outcomes in severe sepsis and 
septic shock [55]. Patients with severe sepsis were rand-
omized to receive either 20% albumin and crystalloids or 
crystalloids alone after initial early goal-directed resus-
citation. In patients randomized to albumin treatment, 
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albumin was supplemented for 28  days, to maintain an 
albumin concentration ≥ 30 g/L. Despite some beneficial 
physiologic effects (lower heart rates, higher mean arte-
rial pressure, and lower daily net positive fluid balance 
over the first 7 days), no difference was observed either 
in mortality at 90  days (41.1% vs. 43.6%) or in overall 
organ failure scores. However, when analyzing the results 
according to disease severity, patients with septic shock 
randomized to albumin supplementation showed a lower 
risk of death (relative risk 0.87; 95% confidence interval—
CI 0.77–0.99) as compared to those just receiving only 
crystalloids. It is worth mentioning that this trial did not 
utilize albumin as a resuscitation fluid, but as a drug to 
correct hypoalbuminemia.
The case against albumin
Colloids should remain in the intravascular space longer 
than crystalloids, provided that the endothelial barrier is 
intact, which is often not the case in critically ill patients 
[56]. Given the recent discussion on the potential adverse 
effects of artificial colloids, especially of hydroxyethyl 
starches (HES), a renewed interest in the use of albu-
min has emerged. However, despite the strong physi-
ologic rationale and significant scientific effort [55, 57], to 
date, no randomized controlled trial has shown any sig-
nificant benefit of fluid resuscitation using albumin over 
other types of fluids, including crystalloids [58]. Some 
reports have even suggested that albumin administration 
in the setting of cardiac surgery may be associated with 
the development of acute kidney injury [59]. As stated 
previously, one of the largest albumin trials to date, the 
ALBIOS study, reported a reduction in 90-day mortality 
in a subgroup of patients with septic shock. However, this 
result was based on a post-hoc rather than predefined 
analysis and should, therefore, be interpreted with cau-
tion. The results of two ongoing randomized trials, the 
ALBumin Italian Outcome Septic Shock-BALANCED 
Trial (ALBIOSS-BALANCED) and the Albumin Replace-
ment Therapy in Septic Shock (ARISS), may provide 
some answers to the above-mentioned issues.
The significant cost and the availability of equally effec-
tive low-cost alternatives do not play in favor of albumin, 
although a subgroup analysis of the ALBIOS dataset may 
suggest that albumin infusion is likely cost-effective in 
patients’ septic shock [60]. Up to date, the theoretical 
benefits of albumin are not supported by sound clinical 
evidence, and the case for albumin remains controversial.
Perioperative fluid management
The aim of perioperative fluid therapy, in parallel with the 
maintenance of the effective circulating blood volume, is 
to avoid both fluid overload and under-hydration, while 
maintaining patients’ fluid balance as close as possible to 
zero. Despite this rationale, it is not unusual for surgical 
patients to receive 5–10  L of fluid and 600–1000  mmol 
of sodium, leading to edema and adverse outcomes [61], 
which is also favored by the marked and mean arterial 
pressure-dependent reduction of the elimination capacity 
of crystalloids [62, 63]. On the other hand, overnight fast-
ing and bowel preparation, when traditionally applied, 
lead to fluid deficits. Apparently, patients develop post-
operative complications when fluid retention exceeds 
2.5 L [32, 64]. Of course, fluid gain depends not only on 
the amount of fluid administered, but also on the capacity 
of the kidney to excrete the excessive fluid and salt [32].
Fluid management before surgery
Fluid therapy is not only meant to compensate intraop-
erative losses but should also take into account those 
occurring prior to surgery, induced by poor water intake, 
bowel preparation, major inflammation associated with a 
stress response, and possibly, hemorrhage. Dehydration, 
however, is difficult to detect through clinical methods.
Many studies examined whether a fluid load is capa-
ble of reducing hypotension caused by the induction of 
general/regional anesthesia. However, results regarding a 
preload strategy have been discouraging [65, 66].
Fluid management during surgery
In response to the ongoing administration of large vol-
umes of crystalloid to patients undergoing major sur-
gery, a ‘fluid restrictive’ strategy has been proposed. For 
example, Brandstrup et  al. demonstrated in a multi-
center randomized controlled trial that a more restrictive 
regimen was associated with better outcomes follow-
ing colorectal surgery [61]. However, the regimen was 
restrictive compared with the standard of care that was 
excessive (e.g., 5  L positive balance due to high crystal-
loid volumes) [67]. It is therefore conceivable that the 
group with a better outcome rather benefitted from the 
avoidance of fluid excess than from fluid restriction. The 
interpretation of the literature on the topic is hampered 
by the use of very heterogeneous definitions [68]. What 
is however clear from observational studies is that both 
too much and too little fluid are associated with poor 
outcomes [69–72]. Recently, a large cohort study from 
500 U.S. hospitals including adult patients having colon, 
rectal or primary hip or knee surgery was concluded [72]. 
A significant association was found between liberal fluid 
administration on the day of surgery and worse outcomes 
(increased total costs and length of stay in all patients), 
as well as increased presence of postoperative ileus, in 
patients undergoing colorectal surgery. Interestingly, the 
authors also observed that restrictive fluid utilization (the 
lowest 25% by volume) was also associated with worse 
outcomes.
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It is common in Enhanced Recovery after Surgery 
(ERAS) protocols to find the term “intraoperative fluid 
restriction” [73]. However, alternative terms, such as 
“zero balance” or the avoidance of salt and water excess, 
are also available. Protocols advocate the infusion of bal-
anced crystalloid of 1–3  ml/kg/h and to give additional 
boluses of fluid only to match needs judged by either 
measured volumes lost during surgery, or the assess-
ment of peripheral perfusion (such as according to the 
so-called ‘Goal-Directed Fluid Restriction’) [74]. Overall, 
the literature suggests that algorithm-based perioperative 
fluid regimens result in improved patient outcomes.
Fluid management after surgery
Fluid management in postoperative patients is a key 
determinant of their outcomes. While restoring effective 
volume is critical for these patients, fluid management 
should not compromise healing processes. Optimal fluid 
management should thus target efficient central hemo-
dynamics and tissue perfusion while avoiding positive 
net fluid balance. In theory, colloids offer the advantages 
over crystalloids of higher plasma expansion capacity 
and longer plasma half-life. They have the theoretical 
disadvantage of delaying clotting time and increasing 
the risk of kidney injury. In randomized trials, the ratio 
of the cumulative dose of colloids over the cumulative 
dose of crystalloids ranged roughly from 0.41 to 1 [75]. 
In patients with overt clinical hypovolemia, colloids 
were superior to crystalloids in improving cardiac fill-
ing pressures and performance [76]. Likewise, in a large 
multinational randomized trial performed in critically ill 
patients with acute hypovolemia, colloids reduced vaso-
pressor and ventilator dependency when compared to 
crystalloids [77]. A recent systematic review of resuscita-
tion with HES in surgical critically ill patients identified 
13 randomized trials [78]. However, this review found 
no statistically significant difference between HES and 
crystalloids, in terms of mortality (risk ratio 2.97; 95% CI 
0.96 to 9.19; I2 =  0%), need for renal replacement therapy 
(risk ratio 1.11; 95% CI 0.26 to 4.69; I2 =  34%), and major 
infectious complications (risk ratio 1.19; 95% CI 0.59 to 
2.39; I2 =  0%). It is worth mentioning that eligible trials 
were too small to draw firm conclusions on this issue.
It should also be stated that there are opposing views 
regarding the use of starches [79]. For example, several 
criticisms regarding the CHEST trial have been put for-
ward which still require to be addressed [80, 81]. Further-
more, it can be stated that in the CHEST trial starches 
were administered to patients that were not hypov-
olemic. On the other hand, the  CRISTAL trial (where 
70% of the colloid group received HES) concluded that 
significantly less volume was required to achieve hemo-
dynamic stability for HES vs. NaCl in the initial phase of 
fluid resuscitation in severe sepsis patients without any 
difference for adverse events in both groups [77]. Tak-
ing these opposing views into consideration, the ongoing 
debate about the use of starches in hypovolemic critically 
ill patients still requires more data.
Among patients undergoing major abdominal surgery, 
the recent results of the FLASH trial, showed no signifi-
cant difference in a composite outcome of death or major 
postoperative complications within 14 days after surgery 
[82].
Pending the results of ongoing trials, there are cur-
rently insufficient data to ban the use of colloids in the 
surgical intensive care unit.
Many patients undergoing surgery are not able to 
ingest food or fluids for some time following surgery 
and will require maintenance fluids. Recently, a debate 
emerged on the tonicity of these solutions: although 
guidelines traditionally recommended the use of hypo-
tonic maintenance fluids, in pediatric literature, these 
were shown to be associated with an increased incidence 
of symptomatic hyponatremia [83, 84]. The recent rand-
omized controlled TOPMAST trial in adults undergoing 
major thoracic surgery found this problem to be mild in 
these patients. Isotonic maintenance fluids, on the other 
hand, were associated with a considerably larger positive 
cumulative fluid balance (estimated at 1.4L more positive 
under fluids containing 154 compared to 54  mmol/L of 
sodium) [85].
Fluid overload
The problem with fluid overload in the perioperative 
setting
A certain degree of hypervolemia is necessary to main-
tain organ perfusion during anesthesia and surgery. 
However, fluid given after the induction of anesthesia 
mainly increases “unstressed” blood volume, because 
vasodilatation occurs as a consequence of anesthesia. 
At this point, additional fluid administration is needed 
to optimize stroke volume, i.e., to add to the “stressed” 
intravascular volume [86]. Many clinicians still consider 
this “wet” approach as the gold standard for intraopera-
tive fluid therapy [87], although intravascular volume 
expansion certainly bears some dangers. Myocardial 
work and cardiac pressures increase when infused flu-
ids have exceeded the degree of anesthesia-induced 
vasodilatation. Moreover, fluid overload reduces the 
colloid osmotic pressure that, together with raised car-
diac pressures, might promote pulmonary edema [88]. 
These issues are of particular relevance in patients with 
poor cardiovascular status. Finally, hypervolemia may 
be responsible for another important effect: the release 
of atrial natriuretic peptides (ANPs) to the circulation 
caused by the stretching of atrial myocardial fibers [68, 
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89]. Indeed, in response to a rapid infusion of crystal-
loids, ANP levels increase 2- to 3-fold [90–92], there-
fore reducing strain on the circulation by promoting 
natriuresis and capillary leakage of albumin.
The problem with fluid overload in the Intensive Care Unit
Fluid administration is one of the cornerstones of 
hemodynamic resuscitation in critically ill patients. 
How much fluid to give has been the subject of lively 
debate over the years. Too much fluid can have harm-
ful consequences on multiple organ systems, e.g., wors-
ening gas exchange, renal function and wound healing. 
Fluid overload is particularly likely to arise in condi-
tions when capillary permeability is altered due to an 
inflammatory response, such as during sepsis. A posi-
tive fluid balance has been associated with worse out-
comes in several studies in various groups of intensive 
care unit (ICU) patients [16, 93–95]. In patients with 
septic shock, fluid administration and positive fluid 
balance were independently associated with increased 
mortality rates [93, 96]. Similarly, in patients admitted 
to the ICU after major surgery, fluid balance was an 
independent risk factor for death [95]. Indeed, a multi-
modal restrictive fluid strategy aiming for negative fluid 
balance (PAL-treatment) in patients with acute lung 
injury (ALI) was associated with improved outcomes in 
a retrospective study [97].
It has to be acknowledged that a positive fluid bal-
ance could be a marker of disease rather than a pure 
iatrogenic or preventable problem and it would be 
erroneous to assume the default position of under-
resuscitation. Indeed, inadequate resuscitation due to 
insufficient fluid administration may result in poorer 
tissue perfusion and hence organ dysfunction and 
failure, particularly in the early phase of treatment. A 
balance needs to be achieved, such that each patient 
receives sufficient, but not excessive, fluid for her/his 
needs. Crucially, different patients will have different 
needs and baseline fluid status depending on multiple 
factors including age, co-morbid disease and current 
diagnosis. In addition, it is mandatory to consider indi-
ces of fluid tolerance, such as CVP, lung water, oxygena-
tion and hemoglobin levels. Fluid requirements vary 
during the course of illness. As such, fluids must be 
prescribed on an individual patient basis; the prescrip-
tion should be regularly reviewed and tailored to the 
evolving clinical stage. The answer to the question of 
whether fluid overload is a problem in the ICU will thus 
depend on when it is asked. In the acute resuscitation/
salvage phase, fluid administration is generous. While 
fluid overload should always be a concern, a positive 
fluid balance is a specific target of this phase.
Is deresuscitation/de‑escalation the solution?
The term deresuscitation/de-escalation was first sug-
gested in 2012 [98] and finally coined in 2014 [16]. It 
specifically refers to ‘Late Goal-Directed Fluid Removal’, 
which involves “aggressive and active fluid removal 
through diuretics and renal replacement therapy with net 
ultrafiltration”. Deresuscitation/de-escalation is some-
times also used to more loosely refer to the phase of criti-
cal illness and/or the care of a critically ill patient, after 
initial resuscitation, stabilization, and optimization. It is 
characterized by the discontinuation of invasive therapies 
and a reduction of a spurious fluid balance. Late con-
servative fluid management is defined as 2 consecutive 
days of negative fluid balance within the first week of ICU 
stay, and is an independent predictor of survival in ICU 
patients [16].
Fluid overload and a positive cumulative fluid balance 
are associated with increased morbidity and worse out-
comes, as previously discussed. The natural course of 
events after a first insult (such as infection, trauma, etc.) 
is a systemic inflammatory response with increased capil-
lary permeability and organ dysfunction [98]. The pres-
ence of fluid overload and interstitial edema may thus 
trigger a vicious cycle. This is what has been referred 
to as the Ebb phase of shock [16]. In the majority of 
patients, shock reversal occurs (with correct antibiot-
ics and proper source control) and excess fluids can be 
mobilized: this is called the Flow phase [16]. However, 
some patients will not transfer spontaneously from the 
Ebb to Flow phase and will remain in a state of unre-
solved shock with positive cumulative fluid balance, and 
this is where active deresuscitation/de-escalation might 
have an important role.
It is unclear which is the best therapeutic option for 
deresuscitation/de-escalation. The administration of 
albumin in combination with diuretics (20% albumin to 
achieve a serum albumin levels of 30  g/L and furosem-
ide bolus of 60  mg followed by continuous infusion of 
10  mg/h) and the association of this strategy with the 
sequential application of PEEP set to counteract intra-
abdominal pressure (IAP) have been proposed [97]. In 
addition, renal replacement therapy and aggressive ultra-
filtration can be used to achieve a negative fluid balance 
in selected patients [99]. When it comes to deresuscita-
tion/de-escalation, it is important to decide on when, 
how and for how long. For this purpose, we need to use 
the right targets to reach our goals. “Over-deresuscita-
tion” has its drawbacks and may cause neurologic dys-
function in the long run [100].
In conclusion, it is crucial to ensure that the indication 
for fluid resuscitation no longer exists (e.g., absence of 
vasopressor, no lactate, adequate venous oxygen satura-
tion of hemoglobin) before starting with deresuscitation. 
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Furthermore, the 5 steps of Deresuscitation/De-Escala-
tion need to be kept in mind: (1) define a clinical end-
point (e.g., improvement in oxygenation); (2) set a fluid 
balance goal (e.g., 1  L negative balance in 24  h); (3) set 
perfusion and renal safety precautions (e.g., vasopres-
sor need, 25% serum creatinine increase); (4) re-evaluate 
after 24 h unless safety limits reached; (5) adjust the plan 
accordingly.
The 4 phases of fluid therapy and the R.O.S.E. 
or S.O.S.D. concept
Two articles were published recently, almost simultane-
ously, referring to the dynamics of fluid therapy [16, 101]. 
These conceptual models identified four dynamic phases. 
The Acute Dialysis Quality Initiative (ADQI) group pro-
posed S.O.S.D. (Salvage, Optimization, Stabilization, 
De-escalation) as acronym [101]. However, during the 
International Fluid Academy Day (IFAD) meetings there 
was a clear preference for the R.O.S.E. acronym (Resus-
citation, Optimization, Stabilization, Evacuation) as sum-
marized below, in Fig. 1 and Table 3. We tried to suggest 
endpoints and targets for the different phases; however, it 
was decided not to include them because there cannot be 
a specific target of cardiac index and PPV must be con-
sidered only if cardiac output is low. A high PPV is often 
a physiological state and defining a “normal” state when 
a low PPV value is reached might lead to unnecessary 
fluid infusion [102]. Also, defining a given preload level as 
a target of resuscitation is senseless as it may shift from 
patient to patient and from time to time.
Resuscitation phase (R) or salvage phase (S)
In the first, salvage/resuscitation phase, when a patient 
presents with hemodynamic shock, the aim of the treat-
ment is resuscitation and correction of shock with the 
achievement of an adequate perfusion pressure. A rapid 
fluid bolus should be given (although the exact amount 
can vary, usually 3–4 mL/kg given over 10 to 15 min and 
repeated when necessary), normally in association with 
vasopressor administration. In parallel, emergency proce-
dures to resolve any obvious underlying cause should be 
performed, with hemodynamic monitoring initiated. In 
this phase, the goal is early adequate goal-directed fluid 
management: fluid balance must be positive. We do not 
support blind adherence to the surviving sepsis campaign 
guidelines adagio to administer 30 ml/kg of fluids within 
the first hour for all patients, as explained previously [9]. 
This may lead to either over- or under resuscitation in 
some patients. Every patient needs an individual and per-
sonalized approach.
Optimization phase (O)
The optimization phase starts when the patient is no 
longer in overt absolute/relative hypovolemia, but 
remains hemodynamically unstable. Some form of moni-
toring will by now be in place. Fluids should be admin-
istered according to individual needs, reassessed on a 
regular basis, e.g., using fluid challenge techniques [103, 
104]. Fluid challenges must be conducted carefully, bear-
ing in mind the four essential components (TROL): Type 
of fluid (e.g., a balanced crystalloid-like PlasmaLyte); Rate 
(e100–200 mL over 10 min); Objective (e.g., normal arte-
rial pressure or heart rate); and Limits (e.g., high cen-
tral venous pressure level) (Fig. 2) [105]. The aim of this 
phase is to optimize and maintain adequate tissue perfu-
sion and oxygenation in order to prevent and limit organ 
damage. The patient must be carefully monitored during 
the optimization phase: often several types of monitoring 
(e.g., arterial catheter, echocardiography, central venous 
pressure, arteriovenous blood gas) are required to obtain 
the most complete picture of a patient’s hemodynamic 
status.
Although a resuscitation based on microcirculatory 
endpoints is expected to result in analogous amelioration 
in the microcirculation, a lack of coherence may exist 
between macro- and microcirculation. Thus, markers 
of hypoperfusion should include also lactate, prolonged 
capillary refill time and mottling score [106].
Stabilization phase (S)
Once the patient is stable, the stabilization phase begins 
and evolves over days. In this phase, the aim of fluid man-
agement is to ensure water and electrolytes to replace 
ongoing losses and provide organ support. The tar-
get should be a zero or slightly negative fluid balance. 
It might be of interest, in this context, to underline the 
Fig. 1 The R.O.S.E. concept and the 4 phases of Fluid Therapy. Adapted according to the Open Access CC BY Licence 4.0 with permission from 
Malbrain et al. [9]. a Graph showing the four-hit model of shock with evolution of patients’ cumulative fluid volume status over time during 
the five distinct phases of resuscitation: Resuscitation (R), Optimization (O), Stabilization (S), and Evacuation (E) (ROSE), followed by a possible 
risk of Hypoperfusion in case of too aggressive deresuscitation. On admission patients are hypovolemic, followed by normovolemia after fluid 
resuscitation (EAFM, early adequate fluid management), and possible fluid overload, again followed by a phase going to normovolemia with late 
conservative fluid management (LCFM) and late goal-directed fluid removal (LGFR) or deresuscitation. In case of hypovolemia,  O2 cannot get into 
the tissues because of convective problems, in case of hypervolemia  O2 cannot get into the tissue because of diffuse problems related to interstitial 
and pulmonary edema, gut edema (ileus and abdominal hypertension). b The role of fluids within the R.O.S.E. concept
(See figure on next page.)
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Panel B 
Panel A 
Resuscitation
• Aim of the fluid treatment is resuscitation and correction of 
shock with the achievement of an adequate perfusion 
pressure
Optimization
• Fluids should be administered according to individual 
needs and reassessed on a regular basis
Stabilization
• Aim to provide water and electrolytes to replace ongoing 
losses and provide organ support
Evacuation
• Removing excessive fluid which will be frequently achieved 
by spontaneous diuresis as the patient recovers, although 
ultrafiltration or diuretics might be necessary
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fact that in the major trials suggesting a harmful effect 
of starches [2, 107], these colloids were given abundantly 
also in the stabilization phase, i.e., in a phase that possi-
bly did not require these drugs.
Evacuation phase (E) or de‑escalation phase (D)
The final phase is evacuation or de-escalation, with the 
purpose of removing excessive fluid. This will be fre-
quently achieved by spontaneous diuresis as the patient 
recovers, although ultrafiltration or diuretics might be 
necessary. Of note, it was recently shown that diuretics 
might favor the recruitment of microcirculation, thus 
decreasing diffusion distances and improving oxygen 
extraction [108].
Fluid management in trauma and burns
Fluid management in acute hemorrhagic shock 
following trauma
Although traumatic brain injury remains the commonest 
cause of death following severe blunt injury, concomitant 
major hemorrhage will result in cerebral hypoperfusion, 
which undoubtedly contributes to secondary brain injury 
and death. As such, hemorrhage remains the most pre-
ventable cause of trauma mortality.
An adequate intravascular volume, hemoglobin con-
centration and oxygen saturation are essential to main-
tain aerobic metabolism. Humans do not tolerate 
anaerobic metabolism and 90% of oxygen consumption is 
used in the formation of adenosine triphosphate (ATP), 
the major energy source for cell function. Rapid reversal 
of anaerobic metabolism is imperative to restore ATP and 
prevent irreversible cellular apoptosis and death [109].
• e.g. normalisaon 
of MACRO (arterial 
pressure, heart 
rate, CO) and 
MICRO-circulaon
• e.g. increased 
CVP, PVPI, 
EVLWI
• e.g. 4ml/kg  
over 5-10 
minutes
• e.g. crystalloid 
vs colloid
• e.g. balanced vs 
unbalanced
Type Rate
ObjecveLimits
Fig. 2 The TROL mnemonic of fluid challenge: considerations for administration of a fluid bolus in critically ill patients. CO cardiac output; CVP 
central venous pressure; EVLWI extra vascular lung water index; PVPI pulmonary vascular permeability index (Adapted from Vincent and Weil [97])
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Recognizing that hypovolemia is the consequence of 
hemorrhagic shock, past strategies utilized crystalloids 
to restore intravascular volume, followed by blood trans-
fusion. Crystalloids, however, do not carry oxygen, and 
oxygen delivery may only be enhanced by an adequate 
hemoglobin concentration. Furthermore, major hemor-
rhage is accompanied by a unique coagulation disorder, 
the Acute Coagulopathy of Trauma and Shock (ACoTS) 
[110], leading to poor clot formation, as a result of 
increased binding of thrombin to thrombomodulin and 
enhanced fibrinolysis. Dilution of coagulation factors, 
acidosis, and hypothermia play a secondary role in this 
scenario. The approach to resuscitation must therefore be 
proactive and not reactive with the combined administra-
tion of packed red blood cells, plasma, platelets, and cry-
oprecipitate. The use of clear resuscitation fluids should 
be minimized. Based on military experience, the recom-
mended ratio of packed red blood cells to plasma and 
platelets should be 1:1:1. The endpoints for hemoglobin 
concentration of 10 g/dL, a platelet count of > 50,000, an 
INR < 1.5 and a fibrinogen concentration of > 1  g/L can-
not be generally recommended. In addition, the ionized 
calcium level should be > 1.0 mmol/L.
While the above is a general recommendation, not all 
patients will require such an aggressive approach [111]. 
Indeed, over-zealous transfusion is associated with 
unwanted complications.
The standard approach has been to use conventional 
laboratory coagulation testing to determine the need 
for component therapy. These, however, are performed 
at room temperature and do not reflect individual steps 
in coagulation. Thromboelastometry has now been rec-
ognized as an essential tool to monitor coagulopathy in 
trauma [112]. This device reflects the entire process of 
coagulation and can graphically determine the need for 
specific coagulation factors. Unlike laboratory coagula-
tion studies, modern thromboelastometry machines may 
be set to the patient’s core temperature and accurately 
reflect the in vivo coagulation status. These instruments 
should be the standard of care in centers handling major 
trauma.
Following the CRASH-2 trial indicating the benefit of 
tranexamic acid given within 3 h from injury, such treat-
ment has been included in many protocols for major 
hemorrhage [112]. In the presence of a sophisticated 
trauma system, the benefits are doubtful and further data 
are warranted [113].
Fluid management in burns
The understanding of burn shock pathophysiology and 
subsequent development of fluid resuscitation strate-
gies resulted in dramatic outcome improvements in 
burn care during the last decades [114]. However, while 
under-resuscitation has become rare in clinical practice, 
there is growing concern that over-resuscitation, leading 
to increased morbidity and mortality, has become more 
of an issue in burn care. In the late sixties of the previ-
ous century, Baxter and Shires developed their landmark 
formula at the Parkland Memorial Hospital, which has 
lasted decades as the gold standard for fluid resuscita-
tion in acute burn care across the world [115]. The for-
mula advocates 4  ml crystalloids per kg per % of total 
body surface area for 24 h, of which half is given during 
the first 8 h. Diuresis (target 1 ml/kg/h) is used to guide 
the amount of intravenous fluids. During the second 24 h 
of resuscitation, colloids are allowed, and resuscitation 
volume is adapted according to diuresis (with a gradual 
decrease if diuresis is adequate).
However, over the last 15 years, multiple centers have 
reported excess fluid administration [116, 117]. This 
fluid excess often leads to “resuscitation morbidity”, a 
group of complications linked to fluid overload, such 
as delayed wound healing, delayed recovery of gastro-
intestinal function (with ileus), pulmonary edema (due 
to capillary leak and increased extravascular lung water), 
limb compartment syndrome, orbital compartment syn-
drome, intra-abdominal hypertension and abdominal 
compartment syndrome leading to multiple organ failure 
[118–120].
This discrepancy between the predicted and the admin-
istered fluid is known as “fluid creep”, a term brought to 
life by Basil Pruitt [119].
Recommendations for fluid resuscitation in burns are 
listed in Table 4. The most well-known adverse effect of 
NaCl 0.9% is hyperchloremic metabolic acidosis. Given 
the large infusion volumes administered to burn patients, 
balanced solutions are preferred. Indeed, since the begin-
ning of burn resuscitation, most formulae advocate the 
use of balanced crystalloid solutions. Of note, an obser-
vational study reported lower Sequential Organ Failure 
Assessment (SOFA) scores in severely burned patients 
resuscitated with acetated Ringer’s [121].
The use of colloids in the first 24  h has been contro-
versial since it was thought that the existing capillary leak 
would allow large molecules to leak out into the extravas-
cular space and exert an osmotic pull increasing the 
formation of edema [122]. In the last 15 years, renewed 
interest in colloids has arisen during burn resuscitation, 
instigated by the awareness of morbidity related to resus-
citation and fluid creep. Until recently, the low molecular 
weight HES solutions were widely used as a resuscitation 
fluid in critically ill ICU, surgery and burn patients. How-
ever, after large fluid trials, including the CHEST and 
6S trials, showing increased mortality and a higher rate 
of renal replacement therapy have raised alarming con-
clusions regarding the safety of HES solutions, starches 
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can no longer be used in burn injuries as recommended 
by the Pharmacovigilance Risk Assessment Committee 
(PRAC) [2, 107, 123].
Albumin is a natural plasma protein that contrib-
utes most to intravascular oncotic pressure in humans 
(see above). The most common solutions are 4%, 
5% or 20% albumin. It is a relatively expensive solu-
tion and its availability may be limited in some coun-
tries. Although albumin resuscitation has been used 
with some reservations, especially in the acute phase 
of burn resuscitation, trials provide promising data 
regarding the use of albumin as an adjunctive therapy 
in burn resuscitation [124, 125]. Similarly, hypertonic 
saline has been used for decades in burn resuscitation; 
theoretically, it expands the circulating volume by an 
intravascular water shift. Proponents claim that this 
process will decrease tissue edema and will lower the 
rate of complications. This hypothesis, however, needs 
to be confirmed by further studies.
Take home messages and considerations prior to IV 
fluid prescription
Consider the 5 Ps of fluid prescription as shown in Fig. 3 
and tailor the IV fluids to the patient’s need via individ-
ualized and personalized care (Table  5) [126]. Prescrip-
tion safety can be summarized by the ‘4 Ds’ principle as 
explained above [4]:
– Drug—which fluid.
– Dose—calculate how much to give.
– Duration—duration of the IV fluid therapy.
– De-escalation—stop it as soon as possible.
The bottom line is “Give the right fluid in the right 
dose to the right patient at the right time”
Conclusions
The prescription of fluid therapy is one of the most 
common medical acts in hospitalized patients but many 
of the aspects of this practice are surprisingly complex. 
It is time to introduce fluid stewardship in your ICU. 
Table 4 Recommendations regarding fluid resuscitation in severe burns’ patients. Adapted from Peeters et al. [106] with 
permission
Type of fluid Recommendation
1. Normal saline Given the fact that fluid resuscitation in burn management requires large volumes, the use of saline cannot be recom-
mended in a burn resuscitation protocol
2. Balanced crystalloid Based on the available evidence, balanced crystalloid solutions are a pragmatic initial resuscitation fluid in the majority of 
acutely ill (and burn) patients
3. Semi-synthetic colloids Given the recent data concerning the use of semi-synthetic colloids (and starches in particular), their use in critically ill 
patients, including burn patients, cannot be recommended
4. Albumin Based on the available evidence the use of albumin 20% can be recommended in severe burns, especially in the deresus-
citation phase guided by indices of capillary leak, body weight, (cumulative) fluid balance, fluid overload, extravascular 
lung water and IAP
5. Hypertonic solutions To this day, there is insufficient evidence to reach consensus regarding the safety of hypertonic saline in burn resuscitation. 
Whenever using hypertonic saline in clinical practice, however, close monitoring of sodium levels is highly advised
A. Physician B. Prescription C. Pharmacy D. Preparation E. Patient
Fig. 3 The 5 Ps of fluid administration. a Physician: All starts with the physician’s participation in making decisions related to fluid management. b 
Prescription: The physician should engage in writing a prescription that accounts for drug, dose, duration and whenever possible de-escalation. c 
Pharmacy: The prescription is sent to the pharmacy and is checked for inconsistencies by the pharmacist to get a more holistic view. d Preparation: 
The process by which the prescription is prepared and additions (e.g., electrolytes) made. e Patient: The filled prescription goes back to the patient 
and fluid stewards should observe administration, response, and debrief
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To avoid fluid-induced harm, we recommend a care-
ful evaluation of the chosen solution and a phase-wise 
approach to its administration, taking into account the 
clinical course of the disease or surgical procedure. 
Fluids should be prescribed with the same care as any 
other drug and every effort should be made to avoid 
their unnecessary administration.
Table 5 The four stages to  check for  appropriateness of  IV fluid therapy. Adapted with permission from Malbrain ML 
et al. [126]
Stage of evaluation Audit standard
1. Assessment The patient’s fluid balance (via fluid chart with input and output) is assessed on admission in the hospital and on a day-by-day 
basis
The patient’s weight is assessed within the last 3 days of fluid prescription
The patient’s fluid and electrolyte needs are assessed as part of every ward review
The assessment of the patient’s fluid status (hypo/eu/hypervolemia) includes the use of clinical judgement, vital signs and fluid 
balance with urine output
Recent lab results with urea and electrolytes (within 24 h of fluid prescription)
If possible sodium balance should be reported
2. Indication A. Resuscitation
 For patients in need of fluid resuscitation:
  The cause of the fluid deficit is identified
  An assessment of shock or hypoperfusion was made
  A fluid bolus of 4 mL/kg of balanced crystalloids is given
 Fluid responsiveness is assessed with functional hemodynamics, passive leg raising test or end-expiratory occlusion test, or a 
combination
 Mean arterial pressure and cardiac output are monitored continuously via pulse contour analysis allowing assessment of beat-
to-beat variations
 Patients who have received initial fluid resuscitation are reassessed within 30 min
 Care is upgraded in patients who have already been given > 2000 mL of crystalloids and still need fluid resuscitation after reas-
sessment
 Patients who have not had > 2000 mL of crystalloids and who still need fluid resuscitation after reassessment receive 2–4 mL/kg 
of crystalloids and have a further reassessment
B. Maintenance
 If patients need IV fluids for routine maintenance alone, the initial prescription is restricted to
  25–30 mL/kg/day (1 mL/kg/h) of water and
  Approximately 1 mmol/kg/day of potassium  (K+) and
  Approximately 1–1.5 mmol/kg/day of sodium  (Na+) and
  Approximately 1 mmol/kg/day of chloride and
  Approximately 50–100 g/day (1–1.5 g/kg/day) of glucose to limit starvation ketosis
 Definition of inappropriateness in case of electrolyte disturbances
  Solutions not containing adequate amount of sodium in case of hyponatremia (Na < 135 mmol/L)
  Solutions not containing adequate amount of potassium in case of hypokalemia (K < 3.5 mmol/L)
  Solutions containing too much sodium in case of hypernatremia (Na > 145 mmol/L)
  Solutions containing too much potassium in case of hypokalemia (K > 5 mmol/L)
 The amount of fluid intake via other sources should be subtracted from the basic maintenance need of 1 ml/kg/h:
  Enteral or parenteral nutrition
  Fluid creep (see further)
C. Replacement and redistribution
 If patients have ongoing abnormal losses or a complex redistribution problem, the fluid therapy is adjusted for all other sources 
of fluid and electrolyte losses (e.g., normal saline may be indicated in patients with metabolic alkalosis due to gastro-intestinal 
losses)
D. Fluid creep
  All sources of fluids administered need to be detailed: crystalloids, colloids, blood products, enteral and parenteral nutritional 
products, and oral intake (water, tea, soup, etc.)
  Precise data on the concentrated electrolytes added to these fluids or administered separately need to be collected
  Fluid creep is defined as the sum of the volumes of these electrolytes, the small volumes to keep venous lines open (saline or 
glucose 5%), and the total volume used as a vehicle for medication
3. Prescription  The following information is included in the IV fluid prescription:
  The type of fluid
  The rate of fluid infusion
  The volume or dose of fluid
 The IV fluid prescription is adapted to current electrolyte disorders and other sources of fluid intake
4. Management Patients have an IV fluid management plan, including a fluid and electrolyte prescription over the next 24 h
The prescription for a maintenance IV fluid only changes after a clinical exam, a change in dietary intake or evaluation of labora-
tory results
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Abbreviations
4 Ds: Drug—Dose—Duration—De-escalation; ANP: Atrial natriuretic peptide; 
ATP: Adenosine triphosphate; CI: Confidence interval; ERAS: Enhanced recov-
ery after surgery; HES: Hydroxyethyl starch; IAP: Intra-abdominal pressure; ICU: 
Intensive care unit; PEEP: Positive end-expiratory pressure; ROSE: Resuscita-
tion—Optimization—Stabilization–Evacuation; SID: Strong ion difference; 
SOFA: Sequential Organ Failure Assessment.
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